Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker

The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glio...

Full description

Saved in:
Bibliographic Details
Published inThe journal of gene medicine Vol. 25; no. 10; p. e3517
Main Authors Tang, Qikai, Mao, Xiaoman, Chen, Zhengxin, Ma, Chenfeng, Tu, Yiming, Zhu, Qianmiao, Lu, Jiacheng, Wang, Zhen, Zhang, Qixiang, Wu, Wei
Format Journal Article
LanguageEnglish
Published England Wiley Periodicals Inc 01.10.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid-liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co-expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo-time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK-8 assays, clone generation assays, transwell assays and wound healing assays. FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo-time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines. Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment.
AbstractList Abstract Background The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. Methods The single cell sequencing dataset scRNA‐6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid–liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co‐expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo‐time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK‐8 assays, clone generation assays, transwell assays and wound healing assays. Results FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo‐time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines. Conclusions Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment.
The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid-liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co-expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo-time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK-8 assays, clone generation assays, transwell assays and wound healing assays. FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo-time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines. Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment.
BackgroundThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis.MethodsThe single cell sequencing dataset scRNA‐6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid–liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co‐expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo‐time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK‐8 assays, clone generation assays, transwell assays and wound healing assays.ResultsFABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo‐time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines.ConclusionsOur study provides a new biomarker, FABP5, for glioma diagnosis and treatment.
Author Tang, Qikai
Chen, Zhengxin
Wang, Zhen
Wu, Wei
Zhu, Qianmiao
Lu, Jiacheng
Ma, Chenfeng
Zhang, Qixiang
Mao, Xiaoman
Tu, Yiming
Author_xml – sequence: 1
  givenname: Qikai
  surname: Tang
  fullname: Tang, Qikai
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 2
  givenname: Xiaoman
  surname: Mao
  fullname: Mao, Xiaoman
  organization: Department of Neurosurgery, Pukou Branch of Jiangsu People's Hospital, Nanjing Pukou District Central Hospital, Nanjing, China
– sequence: 3
  givenname: Zhengxin
  surname: Chen
  fullname: Chen, Zhengxin
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 4
  givenname: Chenfeng
  surname: Ma
  fullname: Ma, Chenfeng
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 5
  givenname: Yiming
  surname: Tu
  fullname: Tu, Yiming
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 6
  givenname: Qianmiao
  surname: Zhu
  fullname: Zhu, Qianmiao
  organization: Department of Neurosurgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
– sequence: 7
  givenname: Jiacheng
  surname: Lu
  fullname: Lu, Jiacheng
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 8
  givenname: Zhen
  surname: Wang
  fullname: Wang, Zhen
  organization: Department of Orthopaedics, Jinling Hospital, Nanjing Medical University, Nanjing, China
– sequence: 9
  givenname: Qixiang
  surname: Zhang
  fullname: Zhang, Qixiang
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
– sequence: 10
  givenname: Wei
  surname: Wu
  fullname: Wu, Wei
  organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37114595$$D View this record in MEDLINE/PubMed
BookMark eNpdkEtP3DAUha2KqgO0Er8AWWLTTcDXb7MDVB7SSGVBpa4auZmbwUNiBztZ9N830w4gsTp38eno3O-A7MUUkZAjYKfAGD_brPtTocB8IPugOFScK7k338y5Sjr7c0EOStkwBsZa94kshAGQyql98msZnqewqrp_QYdHX5AWHHz2Y0ixytj5EVd0jRFpiHTdhdT7ck6vLy7vFQ2FejqkEeMYfEeHnNYxlTE0tPf5CfNn8rH1XcEvuzwkP66_PVzdVsvvN3dXF8uqEQBjpbXjYDxq67XQjZdCi9bLlnFjGq2kBi5QgrRoQKMSjeeSuabVqAWzRopD8vV_77zgecIy1n0oDXadj5imUnPLjONSuC168g7dpCnHed1MGWaBK7BvhU1OpWRs6yGH-ac_NbB667yenddb5zN6vCucfve4egVfJIu_lNJ8Aw
CitedBy_id crossref_primary_10_1016_j_canlet_2024_216614
Cites_doi 10.1016/j.ncrna.2021.04.003
10.1111/cns.13654
10.1080/14737175.2016.1194755
10.1093/nar/gkz1027
10.1016/j.soncn.2018.10.001
10.7150/thno.44868
10.1007/s11427‐020‐1702‐x
10.1093/neuonc/nou087
10.1016/j.cell.2021.10.001
10.1016/j.drudis.2020.09.018
10.1016/j.devcel.2020.06.033
10.1007/s11910‐013‐0346‐3
10.1016/j.canlet.2020.02.002
10.1093/database/bar026
10.1007/s13311‐017‐0519‐x
10.1158/1078‐0432.CCR‐18‐3626
10.3389/fendo.2021.728088
10.1097/RMR.0000000000000233
10.26355/eurrev_202006_21674
10.1186/1471‐2105‐9‐559
10.1093/nar/gkaa407
10.1016/j.biocel.2017.05.022
10.4103/jcvjs.JCVJS_180_20
10.1007/s10014‐021‐00402‐5
10.1056/NEJMoa1407279
10.1016/j.gpb.2020.10.005
10.1016/j.cancergen.2021.11.001
10.1111/jcmm.16536
10.1093/bioinformatics/bty271
10.1038/s42003‐020‐01367‐5
10.1016/j.nec.2020.09.003
10.1515/revneuro‐2017‐0057
10.1146/annurev‐genet‐112618‐043527
10.3389/fimmu.2022.915709
ContentType Journal Article
Copyright 2023 John Wiley & Sons Ltd.
2023 John Wiley & Sons, Ltd.
Copyright_xml – notice: 2023 John Wiley & Sons Ltd.
– notice: 2023 John Wiley & Sons, Ltd.
DBID NPM
AAYXX
CITATION
7QP
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
DOI 10.1002/jgm.3517
DatabaseName PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
Genetics Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
PubMed
Genetics Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1521-2254
EndPage e3517
ExternalDocumentID 10_1002_jgm_3517
37114595
Genre Journal Article
GrantInformation_xml – fundername: Research Project of Jiangsu Health Commission (No. ZD2022054)
GroupedDBID ---
.3N
.GA
05W
0R~
10A
123
1L6
1OC
29K
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8R4
8R5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BPHCQ
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EBD
EBS
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NPM
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
Q2X
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
SV3
TEORI
UB1
V2E
W8V
W99
WBKPD
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXI
WXSBR
WYISQ
XG1
XV2
ZZTAW
~IA
~WT
.55
.Y3
31~
3V.
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
AASGY
AAYXX
ABUWG
ACBWZ
AFKRA
ASPBG
AVWKF
AZFZN
BBNVY
BDRZF
BENPR
BHPHI
BVXVI
CCPQU
CITATION
EJD
FEDTE
FYUFA
HCIFZ
HF~
HMCUK
HVGLF
LK8
LW6
M0L
M1P
M7P
PQQKQ
PROAC
PSQYO
UKHRP
X7M
7QP
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c311t-669217ae68a636ca4363fa4f0277c6546123e4148e716e53ca2409cf6e6308743
ISSN 1099-498X
IngestDate Fri Oct 25 01:55:30 EDT 2024
Thu Oct 10 22:14:52 EDT 2024
Fri Aug 23 02:52:15 EDT 2024
Sat Sep 28 08:16:21 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords glioma
immune microenvironment
FABP5
liquid-liquid phase separation
bioinformatics
Language English
License 2023 John Wiley & Sons Ltd.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c311t-669217ae68a636ca4363fa4f0277c6546123e4148e716e53ca2409cf6e6308743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 37114595
PQID 2870812518
PQPubID 42608
ParticipantIDs proquest_miscellaneous_2807924394
proquest_journals_2870812518
crossref_primary_10_1002_jgm_3517
pubmed_primary_37114595
PublicationCentury 2000
PublicationDate 2023-10-01
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
PublicationTitle The journal of gene medicine
PublicationTitleAlternate J Gene Med
PublicationYear 2023
Publisher Wiley Periodicals Inc
Publisher_xml – name: Wiley Periodicals Inc
References e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – ident: e_1_2_10_12_1
  doi: 10.1016/j.ncrna.2021.04.003
– ident: e_1_2_10_10_1
  doi: 10.1111/cns.13654
– ident: e_1_2_10_23_1
  doi: 10.1080/14737175.2016.1194755
– ident: e_1_2_10_18_1
  doi: 10.1093/nar/gkz1027
– ident: e_1_2_10_24_1
  doi: 10.1016/j.soncn.2018.10.001
– ident: e_1_2_10_31_1
  doi: 10.7150/thno.44868
– ident: e_1_2_10_14_1
  doi: 10.1007/s11427‐020‐1702‐x
– ident: e_1_2_10_2_1
  doi: 10.1093/neuonc/nou087
– ident: e_1_2_10_15_1
  doi: 10.1016/j.cell.2021.10.001
– ident: e_1_2_10_30_1
  doi: 10.1016/j.drudis.2020.09.018
– ident: e_1_2_10_29_1
  doi: 10.1016/j.devcel.2020.06.033
– ident: e_1_2_10_5_1
  doi: 10.1007/s11910‐013‐0346‐3
– ident: e_1_2_10_4_1
  doi: 10.1016/j.canlet.2020.02.002
– ident: e_1_2_10_17_1
  doi: 10.1093/database/bar026
– ident: e_1_2_10_3_1
  doi: 10.1007/s13311‐017‐0519‐x
– ident: e_1_2_10_25_1
  doi: 10.1158/1078‐0432.CCR‐18‐3626
– ident: e_1_2_10_9_1
  doi: 10.3389/fendo.2021.728088
– ident: e_1_2_10_26_1
  doi: 10.1097/RMR.0000000000000233
– ident: e_1_2_10_34_1
  doi: 10.26355/eurrev_202006_21674
– ident: e_1_2_10_20_1
  doi: 10.1186/1471‐2105‐9‐559
– ident: e_1_2_10_21_1
  doi: 10.1093/nar/gkaa407
– ident: e_1_2_10_22_1
  doi: 10.1016/j.biocel.2017.05.022
– ident: e_1_2_10_6_1
  doi: 10.4103/jcvjs.JCVJS_180_20
– ident: e_1_2_10_28_1
  doi: 10.1007/s10014‐021‐00402‐5
– ident: e_1_2_10_7_1
  doi: 10.1056/NEJMoa1407279
– ident: e_1_2_10_16_1
  doi: 10.1016/j.gpb.2020.10.005
– ident: e_1_2_10_33_1
  doi: 10.1016/j.cancergen.2021.11.001
– ident: e_1_2_10_35_1
  doi: 10.1111/jcmm.16536
– ident: e_1_2_10_19_1
  doi: 10.1093/bioinformatics/bty271
– ident: e_1_2_10_32_1
  doi: 10.1038/s42003‐020‐01367‐5
– ident: e_1_2_10_8_1
  doi: 10.1016/j.nec.2020.09.003
– ident: e_1_2_10_27_1
  doi: 10.1515/revneuro‐2017‐0057
– ident: e_1_2_10_13_1
  doi: 10.1146/annurev‐genet‐112618‐043527
– ident: e_1_2_10_11_1
  doi: 10.3389/fimmu.2022.915709
SSID ssj0017889
Score 2.4514146
Snippet The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in...
Abstract Background The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are...
BackgroundThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required...
BACKGROUNDThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage e3517
SubjectTerms Biomarkers
Brain cancer
Brain tumors
Cholecystokinin
Diagnosis
Gene set enrichment analysis
Gene therapy
Genes
Genomes
Glioblastoma
Glioma
Glioma cells
Infiltration
Leukocyte migration
Lymphocytes T
Macrophages
Metastases
Microenvironments
Polymerase chain reaction
Time series
Transcriptomes
Wound healing
Title Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker
URI https://www.ncbi.nlm.nih.gov/pubmed/37114595
https://www.proquest.com/docview/2870812518
https://search.proquest.com/docview/2807924394
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEBIvaHyubCAj8VZltLHjJryNsWpCZQzUShUvkeM6JbAlpR8S8LQ_AYn_cH8Jd7bzUTQQ0Ie0TaNz5fvpfOe7-5mQpxJeqhsqL1EQq3LBuBfx_tQDOxhNueiJKMDm5Ncn4njMX02CSau1bnaXrJJ99e3KvpL_0SrcA71il-w_aLYSCjfgM-gXrqBhuP6VjofZ5zUM6uoV2Jn52pl_gJWps9SW1Rtcu7KewfStgIMJ8gxVyOwsw-og3BQYHLw4DfBwc9mZFyusIMIOrUWBZXhI6XqOVTyLpieL-GrQThiZvybqR24z-m32SWb13rfZnZ1kEgavoHnoukTew_vsS5bXT9uiAJ2n2i2ybo_Cr6vdmpbwFCa-MMmn5WaRJybnPB6ZI4ZhTXKG2O95YGt401LbFukSkd0rVwDLKPtxdr7PAtsVukmyffImHoyHw3h0NBldI9d9sE9YCfjyXcU61uuH5uTE6m-VnMVd_1kpd9OL-U1oYlyU0Ta55WILemCBcpu0dH6H3LCnjX69SxILl8uLHxYo1ACF1kC5vPjuIEJRnTTLqYPIc2oAQrMllbQCCK0BQi1A7pHx4Gh0eOy5IzY8xXq9lSdEBDGp1CKUggklORMslTzFzL7CPjdwbDSHkFlDXK0DpiR4gJFKhRZIJcnZfbKVF7neITScJon2-4oH04SHXZ2wNFUsDDlLopSHqk2elFMWzy2TSmw5s_0YpjXGaW2TvXIuYwfhZYyp-BD98BBEVD-DFcTUlsx1scZnuv3Ixy7vNnlgdVANwvoQ8wdR8PDPwnfJzRq6e2RrtVjrR-BwrpLHBh4_AdNrgto
link.rule.ids 315,783,787,27938,27939
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Liquid%E2%80%93liquid+phase+separation%E2%80%90related+gene+in+gliomas%3A+FABP5+is+a+potential+prognostic+marker&rft.jtitle=The+journal+of+gene+medicine&rft.au=Tang%2C+Qikai&rft.au=Mao%2C+Xiaoman&rft.au=Chen%2C+Zhengxin&rft.au=Ma%2C+Chenfeng&rft.date=2023-10-01&rft.pub=Wiley+Periodicals+Inc&rft.issn=1099-498X&rft.eissn=1521-2254&rft.volume=25&rft.issue=10&rft_id=info:doi/10.1002%2Fjgm.3517&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-498X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-498X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-498X&client=summon